The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease
ID Vachliotis, SA Polyzos - Current obesity reports, 2023 - Springer
Abstract Purpose of Review To summarize experimental and clinical evidence on the
association between tumor necrosis factor-α (TNF-α) and nonalcoholic fatty liver disease …
association between tumor necrosis factor-α (TNF-α) and nonalcoholic fatty liver disease …
New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. The intricate NAFLD pathogenesis is summarized by the multiple-hits …
worldwide. The intricate NAFLD pathogenesis is summarized by the multiple-hits …
[PDF][PDF] Increased liver localization of lipopolysaccharides in human and experimental NAFLD
Background and Aims Lipopolysaccharides (LPS) is increased in nonalcoholic fatty liver
disease (NAFLD), but its relationship with liver inflammation is not defined. Approach and …
disease (NAFLD), but its relationship with liver inflammation is not defined. Approach and …
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives
H Hu, A Lin, M Kong, X Yao, M Yin, H Xia, J Ma… - Journal of …, 2020 - Springer
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of dysregulated lipid
and glucose metabolism, which is often associated with obesity, dyslipidemia and insulin …
and glucose metabolism, which is often associated with obesity, dyslipidemia and insulin …
[PDF][PDF] The use of rifaximin in patients with cirrhosis
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and
broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative …
broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative …
[HTML][HTML] Endotoxins and non-alcoholic fatty liver disease
T Kessoku, T Kobayashi, K Imajo, K Tanaka… - Frontiers in …, 2021 - frontiersin.org
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide. It occurs with a prevalence of up to 25%, of which 10–20% cases progress to …
worldwide. It occurs with a prevalence of up to 25%, of which 10–20% cases progress to …
The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver damage
from the more prevalent (75%–80%) and nonprogressive nonalcoholic fatty liver (NAFL) …
from the more prevalent (75%–80%) and nonprogressive nonalcoholic fatty liver (NAFL) …
Microbial metabolites: critical regulators in NAFLD
X Dai, H Hou, W Zhang, T Liu, Y Li, S Wang… - Frontiers in …, 2020 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
throughout the world. The relationship between gut microbiota and NAFLD has been …
throughout the world. The relationship between gut microbiota and NAFLD has been …
Molecular and cellular mediators of the gut-liver axis in the progression of liver diseases
A Bruneau, J Hundertmark, A Guillot, F Tacke - Frontiers in Medicine, 2021 - frontiersin.org
The gut-liver axis covers the bidirectional communication between the gut and the liver, and
thus includes signals from liver-to-gut (eg, bile acids, immunoglobulins) and from gut-to-liver …
thus includes signals from liver-to-gut (eg, bile acids, immunoglobulins) and from gut-to-liver …
Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism
J Liu, J Sun, J Yu, H Chen, D Zhang, T Zhang… - npj Biofilms and …, 2023 - nature.com
Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, had no
approved pharmacological agents yet. Obeticholic acid (OCA), a novel bile acid derivative …
approved pharmacological agents yet. Obeticholic acid (OCA), a novel bile acid derivative …